The first experience with brolucizumab for neovascular age-related macular degeneration
DOI: 10.32364/2311-7729-2022-22-2-108-115
A.N. Kulikov, D.S. Maltsev, A.Yu. Malafeeva, S.M. Perminova, V.R. Zhalimova,
A.S. Vasiliev, A.A. Kazak
S.M. Kirov Military Medical Academy, St. Petersburg, Russian Federation
Aim: to assess the efficacy and safety of brolucizumab in Russian patients with neovascular age-related macular degeneration (nAMD).
Patients and Methods: this study enrolled 47 patients with nAMD divided into two groups. Group 1 included 13 treatment-naïve patients/13 eyes (12 men and 1 woman, mean age 72.4±9.5 years, mean best-corrected visual acuity (BCVA) 0.43±0.32). Group 2 included 34 patients having active nAMD despite ongoing treatment/34 eyes (25 men and 9 women, mean age 74.1±8.0 years, mean BCVA 0.46±0.25). All patients received at least two intravitreal injections of brolucizumab (in total, 137 injections) with a 1-month interval. Patients were examined one month after the 2nd injections. BCVA, central macular thickness (CMT), macular volume (MV), sub/intraretinal fluid, and adverse events were evaluated.
Results: in group 1, a significant increase in BCVA from 34.9±6.6 letters to 44.1±4.2 letters (p=0.02) was reported. Meanwhile, in group 2, BCVA remained unchanged (35.0±3.5 letters before treatment vs. 33.8±3.7 letters after treatment, p>0.05). In group 1, CMT and MV significantly reduced, while in group 2, only MV significantly reduced (p<0.05). A significant reduction in the cumulative rate of sub/intraretinal fluid was detected in both groups (p<0.05).
Conclusions: treatment-naïve patients who received brolucizumab demonstrated a significant improvement of anatomical and functional parameters. Meanwhile, patients with active nAMD despite ongoing treatment who received brolucizumab demonstrated a significant reduction in disease activity and tendency to the improvement of anatomical (but not functional) parameters.
Keywords: age-related macular degeneration, brolucizumab, optical coherence tomography, anti-VEGF therapy.
For citation: Kulikov A.N., Maltsev D.S., Malafeeva A.Yu. et al. The first experience with brolucizumab for neovascular age-related macular degeneration. Russian Journal of Clinical Ophthalmology. 2022;22(2):108–115 (in Russ.). DOI: 10.32364/2311-7729-2022-22-2-108-115.
About the authors:
Aleksey N. Kulikov — Dr. Sc. (Med.), Professor, Head of the Department of Ophthalmology, S.M. Kirov Military Medical Academy; 21, Botkinskaya str., St. Petersburg, 194044, Russian Federation; ORCID iD 0000-0002-5274-6993.
Dmitriy S. Maltsev — Dr. Sc. (Med.), Head of the Department of Laser Surgery of the Clinics of Ophthalmology, S.M. Kirov Military Medical Academy; 21, Botkinskaya str., St. Petersburg, 194044, Russian Federation; ORCID iD 0000-0001-6598-3982.
Anna Yu. Malafeeva — Head of Department of Vitreoretinal Surgery of the Clinics of Ophthalmology, S.M. Kirov Military Medical Academy; 21, Botkinskaya str., St. Petersburg, 194044, Russian Federation; ORCID iD 0000-0001-9957-1804.
Sof’ya M. Perminova — clinical resident of the Clinics of Ophthalmology, S.M. Kirov Military Medical Academy; 21, Botkinskaya str., St. Petersburg, 194044, Russian Federation; ORCID iD 0000-0001-5697-5630.
Valeria P. Zhalimova — ophthalmologist of the Clinics of Ophthalmology, S.M. Kirov Military Medical Academy; 21, Botkinskaya str., St. Petersburg, 194044, Russian Federation; ORCID iD 0000-0001-8024-0300.
Aleksandr S. Vasile’v — ophthalmologist of the Clinics of Ophthalmology, S.M. Kirov Military Medical Academy; 21, Botkinskaya str., St. Petersburg, 194044, Russian Federation; ORCID iD 0000-0002-0635-4438.
Alina A. Kazak — clinical resident of the Clinics of Ophthalmology, S.M. Kirov Military Medical Academy; 21, Botkinskaya str., St. Petersburg, 194044, Russian Federation; ORCID iD 0000-0002-6855-2384.
Contact information: Dmitriy S. Maltsev, e-mail: glaz.med@yandex.ru.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 15.02.2022.
Revised 15.03.2022.
Accepted 07.04.2022.
2. Kharakozov A.S., Kulikov A.N., Maltsev D.S. Preferred treatment regimen of aflibercept after treatment interruption in patients with neovascular age-related macular degeneration. Ophthalmology J. 2021;14:17–23 (in Russ.). DOI: 10.17816/OV79934.
3. Brown D.M., Emanuelli A., Bandello F. et al. KESTREL and KITE: 52-week results from two Phase III pivotal trials of brolucizumab for diabetic macular edema. Am J Ophthalmol. 2022;238:157–172. DOI: 10.1016/j.ajo.2022.01.004.
4. Nguyen Q.D., Das A., Do D.V. et al. Brolucizumab: Evolution Through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020;127:963–976. DOI: 10.1016/j.ophtha.2019.12.031.
5. Kulikov A.N., Maltsev D.S., Kazak A.A., Burnasheva M.A. Anterior chamber particles are associated with reduction of intraocular pressure after selective laser trabeculoplasty. Br J Ophthalmol. 2020;104:1508–1511. DOI: 10.1136/bjophthalmol-2019-315445.
6. Dugel P.U., Koh A., Ogura Y. et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127:72–84. DOI: 10.1016/j.ophtha.2019.04.017.
7. Dugel P.U., Singh S.R., Koh A. et al. HAWK and HARRIER: 96-Week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2021;128:89–99. DOI: 10.1016/j.ophtha.2020.06.028.
8. Age-related macular degeneration. Clinical recommendations (approved by the Russian Ministry of Health) (Electronic resource.) URL: https://legalacts.ru/doc/klinicheskie-rekomendatsii-vozrastnaja-makuljarnaja-degeneratsija-utv-minzdravom-rossii (access date: 14.01.2022) (in Russ.).
9. Khanani A.M., Zarbin M.A., Barakat M.R. et al. Safety outcomes of brolucizumab in neovascular age-related macular degeneration: results from the IRIS registry and KOMODO healthcare map. JAMA Ophthalmol. 2022;140:20–28. DOI: 10.1001/jamaophthalmol.2021.4585.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
